EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #78040_C
白介素3
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
总览
白介素 3 (IL-3) 是一种物种特异性的多效性细胞因子，可促进多能造血干细胞和谱系定向祖细胞的存活和增殖，并促进其分化为大多数谱系的成熟细胞，包括嗜碱性粒细胞、中性粒细胞、嗜酸性粒细胞、巨噬细胞、树突状细胞、红细胞和巨核细胞 (Yang et al.; Dorssers et al.; Broughton et al.)。IL-3 由活化的 T 细胞产生，通过促进嗜碱性粒细胞和嗜酸性粒细胞分泌组胺、IL-4 和 IL-6 等炎症介质，在炎症和过敏中发挥生理作用 (Broughton et al.)。 IL-3 受体由一个独特的 α 亚基 (CD123) 和一个 β 共同亚基 (βc 或 CD131) 组成，后者与 IL-5 和 GM-CSF 受体共用，是这些细胞因子的主要信号转导亚基。IL-3 与异二聚体受体结合可激活 JAK/STAT、MAPK 和 PI3K 信号通路 （Woodcock et al.）。
亚型
细胞因子
细胞类型
造血干/祖细胞，多能干细胞
种属
人
研究领域
干细胞生物学
纯度
≥ 97 %
实验数据
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (2)
文献 (1)
Multiple gene knockdown strategies for investigating the properties of human leukemia stem cells and exploring new therapies. Methods in cell biology 2022
Abstract
The past two decades have witnessed significant strides in leukemia therapies through approval of therapeutic inhibitors targeting oncogene-driving dysregulated tyrosine kinase activities and key epigenetic and apoptosis regulators. Although these drugs have brought about complete remission in the majority of patients, many patients face relapse or have refractory disease. The main factor contributing to relapse is the presence of a small subpopulation of dormant drug-resistant leukemia cells that possess stem cell features (termed as leukemia stem cells or LSCs). Thus, overcoming drug resistance and targeting LSCs remain major challenges for curative treatment of human leukemia. Chronic myeloid leukemia (CML) is a good example, with rare, propagating LSCs and drug-resistant cells that cannot be eradicated by BCR-ABL-directed tyrosine kinase inhibitor (TKI) monotherapy and that are responsible for disease relapse/progression. Therefore, it is imperative to identify key players in regulating BCR-ABL1-dependent and independent drug-resistance mechanisms, and their key pathways, so that CML LSCs can be selectively targeted or sensitized to TKIs. Here, we describe several easily adaptable gene knockdown approaches in CD34+ CML stem/progenitor cells that can be used to investigate the biological properties of LSCs and molecular effects of genes of interest (GOI), which can be further explored as therapeutic modalities against LSCs in the context of human leukemia.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.
